Trastuzumab in combination with docetaxel/cisplatin/S-1 (DCS) for patients with HER2-positive metastatic gastric cancer: feasibility and preliminary efficacy-Reference-Cited by-同舟云学术

Trastuzumab in combination with docetaxel/cisplatin/S-1 (DCS) for patients with HER2-positive metastatic gastric cancer: feasibility and preliminary efficacy

Published:2015-06-23 Issue:2 Volume:76 Page:375-382
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Mitsui Yasuhiro,Sato Yasushi,Miyamoto Hiroshi,Fujino Yasuteru,Takaoka Toshi,Miyoshi Jinsei,Kagawa Miwako,Ohnuma Hiroyuki,Hirakawa Masahiro,Kubo Tomohiro,Osuga Takahiro,Sagawa Tamotsu,Sato Yasuhiro,Takahashi Yasuo,Katsuki Shinich,Okuda Toshinori,Takimoto Rishu,Kobune Masayoshi,Nobuoka Takayuki,Hirata Koichi,Kato Junji,Takayama Tetsuji

Funder

TAIHO pharmaceutical Co.,Ltd (Tokyo, Japan)

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-015-2807-7.pdf

Reference20 articles.

1. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63:11–30

2. Garcia M, Jemal A, Ward EM et al (2007) Global cancer facts and figures. American Cancer Society inc, Atlanta

3. Alberts SR, Cervantes A, van de Velde CJ (2003) Gastric cancer: epidemiology, pathology and treatment. Ann Oncol 14:ii31–ii36 Suppl 2